Biodesix, Inc. (NASDAQ:BDSX) Receives $28.33 Consensus PT from Brokerages

Shares of Biodesix, Inc. (NASDAQ:BDSX) have received an average rating of “Moderate Buy” from the five brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $28.3333.

BDSX has been the subject of several research reports. Roth Capital initiated coverage on shares of Biodesix in a research report on Wednesday, June 24th. They set a “buy” rating and a $32.00 price target for the company. HC Wainwright started coverage on shares of Biodesix in a research report on Monday, June 15th. They set a “buy” rating and a $26.00 target price for the company. Canaccord Genuity Group upped their target price on shares of Biodesix from $22.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Finally, Weiss Ratings upgraded shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th.

Biodesix Price Performance

NASDAQ BDSX opened at $21.14 on Friday. The stock has a market capitalization of $219.01 million, a price-to-earnings ratio of -5.21 and a beta of 0.53. Biodesix has a 1-year low of $5.26 and a 1-year high of $24.92. The company has a debt-to-equity ratio of 5.09, a current ratio of 2.82 and a quick ratio of 2.82. The business’s fifty day moving average price is $17.82 and its 200-day moving average price is $14.40.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.32. Biodesix had a negative return on equity of 2,101.40% and a negative net margin of 33.26%.The company had revenue of $25.55 million during the quarter, compared to analyst estimates of $23.12 million. On average, equities analysts predict that Biodesix will post -2.91 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Stempoint Capital LP bought a new stake in Biodesix during the 1st quarter worth approximately $1,015,000. Renaissance Technologies LLC purchased a new stake in shares of Biodesix in the first quarter worth $173,000. Sei Investments Co. bought a new stake in shares of Biodesix during the 1st quarter valued at $624,000. Walleye Capital LLC bought a new position in Biodesix in the 1st quarter worth $157,000. Finally, Cetera Investment Advisers increased its stake in Biodesix by 20.0% in the 1st quarter. Cetera Investment Advisers now owns 12,000 shares of the company’s stock worth $174,000 after buying an additional 2,000 shares in the last quarter. Institutional investors own 20.96% of the company’s stock.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.